GLP1R and pancreatic neoplasm: Taken together, these findings support the hypothesis that GLP-1-based therapies may offer therapeutic benefit not only for metabolic regulation in patients with T2DM but also as adjunctive or supportive agents in oncology, particularly in cancers of the pancreas and liver.